Follow me on Twitter
I agree that content from Twitter will be displayed to me.
Head of Group
Director of Corporate Program
His main research interests are ligand- and structure-based drug design with focus on transmembrane transport proteins, prediction of on- and off-kinetics, as well as semantic data integration.
Publications
Showing entries 321 - 325 out of 328
Fleischhacker, W, Noe, C & Ecker, G 1997, 'Improved Synthesis of the Enantiomers of Propafenone Using chiral Building Blocks', Monatshefte für Chemie, no. 128, pp. 53-59.
Ecker, G, Tumova, I, Racanska, E, Svec, P, Otrusnik, R & Csöllei, J 1997, 'Pharmacological-toxicological evaluation of some newly synthesised analogues of propafenone', Ceska a Slovenska Farmacie, vol. 46, pp. 133-136.
Ecker, G & Chiba, P 1997, 'Recent developments in overcoming tumour cell multi-drug resistance', Expert Opinion on Therapeutic Patents: authoritative analysis of patenting trends, vol. 7, pp. 589-599.
Ecker, G 1997, 'Sodium channel modulators in preclinical and early clinical development', Ion Channel Modulators, vol. 2, pp. 584-591.
Chiba, P, Hitzler, M & Ecker, G 1997, 'Studies on propafenone-type modulators of multidrug resistance III: Variations on the nitrogen', QSAR & Combinatorial Science, vol. 16, no. 5, pp. 361-366. https://doi.org/10.1002/qsar.19970160502
Projects
Molecular Drug Targets
Hering, S. (Project Lead), Ecker, G. (Co-Lead), Maulide, N. (Co-Lead), Weinzinger, A. (Co-Lead) & Gonzalez Herrero, L. (Co-Lead)
1/12/10 → 31/12/22
Project: Research funding